REG - Diaceutics PLC - Notice of AGM and Posting of Annual Report

DiaceuticsAnnouncement

29/05/2024 08:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240529:nRSc1476Qa&default-theme=true

RNS Number : 1476Q  Diaceutics PLC  29 May 2024

 Notice of AGM and Posting of Annual Report

 

Belfast and London, 29 May 2024 - Diaceutics PLC (AIM: DXRX) ("Diaceutics" or
the "Company"), a leading technology and solutions provider to the pharma and
biotech industry announces that it has today posted its Annual Report for the
year ended 31 December 2023 to shareholders together with the Notice of the
2024 Annual General Meeting ("AGM").

The Company will hold its AGM on Monday 24 June 2024 at 10.30 a.m at First
Floor, Building Two, Dataworks at Kings Hall Health and Wellbeing Park,
Belfast, County Antrim BT9 6GW.

The Annual Report and Notice of AGM are now available on the Company's website
at https://bit.ly/44VQLXK (https://bit.ly/44VQLXK)

 

Enquiries:

 

 Diaceutics PLC  
 Nick Roberts, Chief Financial Officer                  Tel: +44 (0)28 9040 6500

 Sally Craig, Company Secretary                         investorrelations@diaceutics.com

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com

 Kinvara Verdon

 Kieran Breheny

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network®.

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAMZGZKKRNGDZM